SG11201405954YA - Treatment of brain cancer - Google Patents

Treatment of brain cancer

Info

Publication number
SG11201405954YA
SG11201405954YA SG11201405954YA SG11201405954YA SG11201405954YA SG 11201405954Y A SG11201405954Y A SG 11201405954YA SG 11201405954Y A SG11201405954Y A SG 11201405954YA SG 11201405954Y A SG11201405954Y A SG 11201405954YA SG 11201405954Y A SG11201405954Y A SG 11201405954YA
Authority
SG
Singapore
Prior art keywords
treatment
brain cancer
brain
cancer
Prior art date
Application number
SG11201405954YA
Other languages
English (en)
Inventor
Patrice A Lee
Shannon L Winski
Kevin Koch
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201405954Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of SG11201405954YA publication Critical patent/SG11201405954YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11201405954YA 2012-03-23 2013-03-25 Treatment of brain cancer SG11201405954YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
PCT/US2013/033751 WO2013142875A1 (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Publications (1)

Publication Number Publication Date
SG11201405954YA true SG11201405954YA (en) 2014-10-30

Family

ID=48048296

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405954YA SG11201405954YA (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Country Status (30)

Country Link
US (3) US20150110780A1 (el)
EP (4) EP3400943B1 (el)
JP (6) JP2015514075A (el)
KR (3) KR102490961B1 (el)
CN (2) CN104203279B (el)
AU (4) AU2013234921A1 (el)
CA (1) CA2867723C (el)
CL (1) CL2014002497A1 (el)
CO (1) CO7071139A2 (el)
CY (2) CY1120204T1 (el)
DK (2) DK3400943T3 (el)
ES (2) ES2673165T3 (el)
HK (1) HK1206276A1 (el)
HR (1) HRP20180659T1 (el)
HU (2) HUE037966T2 (el)
IL (3) IL234627B (el)
LT (1) LT2827900T (el)
MX (1) MX354024B (el)
MY (2) MY174883A (el)
NZ (4) NZ630843A (el)
PH (1) PH12014502032A1 (el)
PL (2) PL3400943T3 (el)
PT (2) PT2827900T (el)
RS (1) RS57140B1 (el)
RU (2) RU2018138976A (el)
SG (1) SG11201405954YA (el)
SI (2) SI2827900T1 (el)
TR (1) TR201808450T4 (el)
UA (1) UA122044C2 (el)
WO (1) WO2013142875A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108498465B (zh) 2011-10-14 2022-05-17 阵列生物制药公司 ErbB2(HER2)抑制剂的固态分散体
SG11201401460PA (en) 2011-10-14 2014-09-26 Array Biopharma Inc POLYMORPHS OF ARRY-380, A SELECTIVE ErbB2 (HER2) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SI2827900T1 (en) 2012-03-23 2018-06-29 Array Biopharma, Inc. Amorphous solid dispersion for use in the treatment of brain cancer
CA3055957A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
KR20200014298A (ko) 2017-04-28 2020-02-10 시애틀 지네틱스, 인크. Her2 양성 암의 치료
JP7139448B2 (ja) * 2018-04-09 2022-09-20 ノボキュア ゲーエムベーハー ＴＴＦｉｅｌｄｓ及びオーロラキナーゼ阻害剤による腫瘍の治療
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
BR112022013169A2 (pt) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea
RS65058B1 (sr) * 2019-12-30 2024-02-29 Deciphera Pharmaceuticals Llc Formulacije inhibitora amorfne kinaze i postupci njihove primene

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
AU2001275107A1 (en) 2000-05-30 2001-12-11 Virginia Commonwealth University Vitamin d3 analogs as radiosensitizers for the treatment of cancer
EP1660090B1 (en) 2003-08-14 2012-11-21 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
AU2005251722B2 (en) 2004-06-03 2009-11-12 Smithkline Beecham (Cork) Limited Cancer treatment method
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
WO2007117749A2 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
US20120052061A1 (en) * 2007-09-24 2012-03-01 Tragara Pharmaceuticals Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
CN108498465B (zh) 2011-10-14 2022-05-17 阵列生物制药公司 ErbB2(HER2)抑制剂的固态分散体
SG11201401460PA (en) 2011-10-14 2014-09-26 Array Biopharma Inc POLYMORPHS OF ARRY-380, A SELECTIVE ErbB2 (HER2) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SI2827900T1 (en) 2012-03-23 2018-06-29 Array Biopharma, Inc. Amorphous solid dispersion for use in the treatment of brain cancer

Also Published As

Publication number Publication date
AU2021261849A1 (en) 2021-12-02
PT2827900T (pt) 2018-06-14
EP3842044A1 (en) 2021-06-30
NZ630843A (en) 2017-01-27
KR102160462B1 (ko) 2020-09-28
HRP20180659T1 (hr) 2018-06-01
JP2022190126A (ja) 2022-12-22
TR201808450T4 (tr) 2018-07-23
JP7404485B2 (ja) 2023-12-25
RU2018138976A (ru) 2018-12-06
CY1123837T1 (el) 2022-05-27
US20230190749A1 (en) 2023-06-22
AU2019203618B2 (en) 2021-08-05
ES2855142T3 (es) 2021-09-23
JP2024019526A (ja) 2024-02-09
NZ756264A (en) 2022-09-30
RU2014142700A (ru) 2016-05-20
SI3400943T1 (sl) 2021-03-31
US11504370B2 (en) 2022-11-22
KR20140139009A (ko) 2014-12-04
US20150110780A1 (en) 2015-04-23
AU2019203618A1 (en) 2019-06-13
PT3400943T (pt) 2021-02-02
CA2867723A1 (en) 2013-09-26
CY1120204T1 (el) 2018-12-12
EP2827900B1 (en) 2018-03-21
SI2827900T1 (en) 2018-06-29
KR102317166B1 (ko) 2021-10-26
MX354024B (es) 2018-02-08
AU2017272232B2 (en) 2019-02-28
CO7071139A2 (es) 2014-09-30
UA122044C2 (uk) 2020-09-10
CN104203279B (zh) 2018-10-30
AU2017272232C1 (en) 2019-08-15
LT2827900T (lt) 2018-05-10
EP4252855A2 (en) 2023-10-04
EP3400943B1 (en) 2020-12-02
RS57140B1 (sr) 2018-07-31
NZ741615A (en) 2019-10-25
IL269205B (en) 2020-06-30
JP2021178820A (ja) 2021-11-18
RU2672575C2 (ru) 2018-11-16
DK3400943T3 (da) 2021-02-08
CA2867723C (en) 2022-11-08
NZ724544A (en) 2018-05-25
CN104203279A (zh) 2014-12-10
PL3400943T3 (pl) 2021-06-14
EP2827900A1 (en) 2015-01-28
KR20210131426A (ko) 2021-11-02
US20190255051A1 (en) 2019-08-22
PL2827900T3 (pl) 2018-08-31
IL234627B (en) 2018-10-31
MY202114A (en) 2024-04-04
IL269205A (en) 2019-11-28
JP2019081792A (ja) 2019-05-30
KR20200115656A (ko) 2020-10-07
KR102490961B1 (ko) 2023-01-19
HK1206276A1 (en) 2016-01-08
PH12014502032A1 (en) 2014-11-24
WO2013142875A1 (en) 2013-09-26
HUE053156T2 (hu) 2021-06-28
DK2827900T3 (en) 2018-05-07
ES2673165T3 (es) 2018-06-20
AU2017272232A1 (en) 2018-01-04
IL261659A (en) 2018-10-31
JP6898960B2 (ja) 2021-07-07
HUE037966T2 (hu) 2018-09-28
MY174883A (en) 2020-05-20
JP2017141302A (ja) 2017-08-17
RU2018138976A3 (el) 2022-04-08
EP4252855A3 (en) 2023-11-15
MX2014011437A (es) 2014-11-10
CL2014002497A1 (es) 2014-11-14
AU2013234921A1 (en) 2014-10-02
JP2015514075A (ja) 2015-05-18
CN109223791A (zh) 2019-01-18
EP3400943A1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL267242B (en) Cancer treatment
IL261659A (en) Brain cancer treatment
HK1214128A1 (zh) 癌症的治療
HK1205254A1 (en) Methods of treatment of cancer
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (en) Treatment of cancer
HK1210023A1 (en) Cancer treatment
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201217890D0 (en) Treatment of cancer
GB201222563D0 (en) Cancer treatment
GB201208296D0 (en) Treatment of cancer
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment